Decrease of natural killer cell activity and monokine production in peripheral blood of patients treated with recombinant tumor necrosis factor by Kist, A. et al.

344 Blood, Vol 72, No 1 (July), 1988: pp 344-348
Decrease of Natural Killer Cell Activity and Monokine Production in Peripheral
Blood of Patients Treated With Recombinant Tumor Necrosis Factor
By Andreas Kist, Anthony D. Ho, Ulrich R#{228}th,Bertram Wiedenmann, Andrea Bauer, Erich Schlick,
Holger Kirchner, and Daniela N. M#{227}nnel
Tumor necrosis factor (TNF). a protein predominantly
produced by activated macrophages/monocytes. is pre-
sently available in recombinant. purified form for clinical
trials. Intensive studies in many laboratories have shown
that besides the tumorcytotoxic effects. TNF acts on a
large array of different cells and has potent immunomodu-
latory activities. In a clinical phase I study. some immuno-
logic functional parameters of blood cells from patients
who received 24-hour infusions of recombinant human TNF
(rhTNF) were analyzed. Natural killer (NK) cell activity. TNF
production. interleukin-1 (IL-i ) production and mitogen-
induced proliferation were measured either in whole blood
T UMOR NECROSIS FACTOR (TNF) was first
described by Carswell et al’ as the active mediator
responsible for the endotoxin-induced hemorrhagic necrosis
of certain mouse tumors. Studies with purified native TNF
as well as with recombinant human-derived and mouse-
derived TNF have confirmed the tumor necrotic activity in
vivo2 as well as tumor cytotoxic activity of the molecule in
vitro.2 However, TNF not only mediated the beneficial
effects of endotoxin, but also the harmful effects of endotoxic
shock, such as fever and hypotension.3’5 In addition, a
plethora of immunomodulatory and cell activating functions
of TNF have been described, especially on macrophages/
monocytes,69 polymorphonuclear leukocytes,’#{176}’2 and endo-
thelial and epithelial cells and fibroblasts.’3”5
Therefore, monitoring some immunologic functions of
peripheral mononuclear leukocytes (PMNLs) of patients
who had received a continuous intravenous (IV) infusion of
recombinant human TNF (rhTNF) for 24 hours once in a
clinical phase I study appeared interesting. Peripheral blood
was drawn before infusion and immediately after comple-
tion. A series of immunologic tests were performed with the
PMNLs obtained. The ability of PMNLs to exhibit natural
killer (NK) cell activity, TNF production, interleukin-1
(IL-I) production, and proliferative responses on mitogenic
stimulation was determined, and the values were compared
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samples or in cultures of peripheral mononuclear leuko-
cytes of the patients directly before and after rhTNF
infusion. NK cell activity. TNF and IL-i production capacity
and proliferative responses to concanavalin A (Con A) were
significantly reduced after rhTNF application. We conclude
from these observations that rhTNF in vivo acts directly or
indirectly on NK cells and monocytes by either inactivating
their functional capacity or by absorbing the relevant cells
to the endothelial cell layer. thus removing them from
circulation.
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to those obtained after TNF application. Considering the
activating effects of TNF on most immunologically impor-
tant cell types and functions under in vitro conditions, it was
surprising that a significant reduction occurred in NK activi-
ty, the TNF and IL-I production capacity, and the conca-
navalin A (Con-A)-induced proliferation of the PMNLs
immediately after infusion of TNF.
MATERIALS AND METHODS
Patients. The patients in this study were treated with recombi-
nant human TNF (rhTNF) according to a protocol for phase I
clinical trial. Patients were eligible for the study if they had
progressive neoplastic diseases refractory to standard chemotherapy
regimens and no alternative treatment was available. They had to
have a performance status of 2, normal renal and hepatic functions,
and no signs of active infections. No cytostatic or immunosuppres-
sive drugs were given for at least 6 weeks before TNF treatment.
Eligible patients were assigned at random to two regimen arms: In
Arm A, patients received a continuous IV infusion of rhTNF for 24
hours once a week (Mondays) for 8 weeks; in arm B, patients
received the same dosage of rhTNF in a 24-hour infusion twice a
week (Mondays and Thursdays) for 8 weeks. The initial dose for
each patient was 0.04 mg/m2/24 h, and subsequent doses were
escalated each week according to a Fibonacci scale until maximum
therapeutic dose (MTD) for the patient was reached. In this study,
all patients were investigated immediately before and after the first
administration of rhTNF (0.04 mg/m2 for 24 hours continuous
infusion) with the exception of one patient, who was studied as he
received 0.08 mg/rn2 of rhTNF.
The protocol of the clinical trial was approved by the Ethics
Commission of the Medical Faculty of the University of Heidelberg,
FRG. Informed consent was obtained from each patient before
accrual into the clinical trial and the laboratory studies. Altogether,
12 patients were studied for NK activity and monokine production:
eight patients with refractory colorectal carcinoma and four with
renal cell carcinoma. Their median age was 57 years (range 38 to 64
years). Ten patients were men and two were women.
Reagents. rhTNF was supplied by Knoll/BASF AG, Ludwigs-
hafen, FRG. The specific activity of the material was 9 x l0 U/mg
protein as measured in the biologic tumor cell (L929) cytotoxicity
assay in the presence of actinomycin D” The pyrogen content was
<1.3 ng/mg protein. Recombinant human IL-la was provided by
J.J. Farrar, Hoffmann La Roche, Nutley, NJ. The specific activity
was 1.7 x l0 U/mg protein based on half-maximal stimulation in
the costimulator assay.’7
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Fig 1. NK cell activity in PMNL preparations obtained from
nine patients before and after rhTNF treatment. Reduction in NK
cell activity after treatment was highly significant (P - .005).
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Preparation of PMNLS. Human PMNLs were prepared from
heparinized blood samples by Ficoll-Paque (Pharmacia, Freiburg,
FRG) density-gradient centrifugation.’8
Determination of NK cell activity. Target cells (K562 tumor
cells) were incubated for 90 minutes with 10 zL 5tCr [sodium
chromate, specific activity 1.85 GBq/mg (18.5 MBq/mL), Behring
AG, Marburg, FRG] in 1 mL RPMI 1640 (GIBCO, Karlsruhe,
FRG) at 37#{176}C.Labeled and washed cells were adjusted to IO
cells/mL. Whole blood was tested at three different dilutions (1:4,
1:8, 1:16) as previously described.’9 PMNLs were tested at three
different concentrations (1 x 106, 5 x i0, 2.5 x 10 cells/mL).
One hundred microliters diluted blood or 100 L PMNL suspension
were mixed with 100 tL target cell preparation in round-bottom
microtiter plates (Nunc, Wiesbaden, FRG) and incubated for four
hours at 37#{176}C.For the maximal release values, the target cells were
lysed by treatment with Triton X-I00 (Sigma, Deisenhofen, FRG);
for the spontaneous release, labeled targets were incubated with
medium alone. Radioactivity released into the supernatant was
measured and the percentage of specific lysis (% specific lysis) was
calculated according to the formula: % specific lysis = 100 x (test
release - low control release/high control release - low control
release).
Determination of Leul 1-positive cells. Human PMNLs (1 x
106) were washed in Hank’s balanced salt solution (HBSS) and
supplemented with 0. 1% sodium azide and I % bovine serum albumin
(BSA). 10 zL offluorescine conjugated (FITC) anti-Leulla (Becton
Dickinson, Heidelberg, FRG) was added to the cells resuspended in
50 ML HBSS. The cell suspension was incubated for 30 minutes on
ice. The cells were washed three times with HBSS and fixed with 1%
paraformaldehyde before the cells were analyzed with FACS at 488
nm gated on lymphocytes.
Determination of TNF and IL-I production capacity. PMNLs
(2 x l06/mL) were cultured in RPMI 1640 (GIBCO), with 10%
heat-inactivated fetal calf serum (FCS) (GIBCO) for 20 hours
either with or without 10 ig/mL Staphylococcus aureus (Pansor-
bin, Calbiochem, Frankfurt, FRG). Cell-free supernatants were
harvested and stored at - 20#{176}Cuntil they were tested for TNF and
IL-i activity.
TNF activity was determined by an enzyme-linked immunospe-
cific assay (ELISA). Plates (96-well flat-bottom, Titertek Immuno
Assay-Plate, Flow Laboratories, Meckenheim, FRG) were coated
with affinity-purified (Protein A-Diasorb, Diagen, D#{252}sseldorf,
FRG), polyclonal rabbit anti-rhTNF antibodies 5 zg/mL in
NaHCO3 buffer (0.05 mol/L, pH 9.0) for 16 hours at 4#{176}C.Serial
dilutions of the test samples in phosphate buffer (0. 1 mol/L, pH 7.5,
2% EDTA, 1% BSA) were applied to the plates for two hours at
room temperature after being blocked with 1% BSA in phosphate-
buffered saline (PBS) for two hours at room temperature. Plates
were washed with PBS containing 0.05% Tween and Biotin (Sigma,
Deisenhofen, FRG)-conjugated affinity-purified (Protein A-Dia-
sorb) polyspecific rabbit anti-rhTNF antibodies, 2.7 g/mL was
added to the wells for 1.5 hours at room temperature. After extensive
washing with PBS containing 0.05% Tween Streptavidin-peroxidase
complex (BRL, Karlsruhe, FRG), a dilution of 1:2,000 was applied
for 30 minutes at room temperature. The plates were washed again
with PBS containing Tween (0.05%) and the substrate solution [3,3’,
5,5’ tetramethylbenzidine, Miles Scientific, MUnchen, FRG, 10 mg
in 100 mL sodium acetate-citric acid buffer (0.1 mol/L, pH 4.9) and
14.7 zL 30% H2O2] was added to the complex. The reaction was
stopped with 2mol/L HSO4, and absorption was measured at 450
nm. The absorption curves obtained with the test samples were
compared with a standard curve obtained with rhTNF and the TNF
content expressed as nanograms per milliliter.
IL- 1 activity was determined by the conventional costimulator
assay.’7 In brief, single-cell suspensions of C3H/HeJ thymocytes
(5 x I05/culture) were cultured in the presence of phytohemagglu-
tinin (PHA-M, 50 ig/mL, Sigma) and serial dilutions of the test
samples for 3 days. The cultures were pulsed with I zCi tritiated
thymidine [(6-3H)thymidine, specific activity 50 Ci/mmol (185
GBq/mmol), Amersham Buchler, Braunschweig, FRG] for six
hours, and incorporated counts were determined. The curves
obtained with the samples were compared with a standard curve
obtained with rhIL-1 and the IL-i content expressed as IL-i units.
Lymphoproliferation assay. Lymphoproliferation was deter-
mined in a whole blood assay as previously described.#{176} Whole blood
was diluted with RPMI 1640 (GIBCO) at a ratio of I to 10. Aliquots
(0.2 mL) were cultured without or with mitogen (phytohemagglu-
tinin PHA 6.25 jg/mL or Con A 6.25 zg/mL both from Sigma) for
6 days at 37#{176}C.The cultures were pulsed with tritiated thymidine
([6-3H] thymidine, specific activity 25 Ci/mmol [925 GBq/mmol]
Amersham Buchler, Braunschweig, FRG) for four hours and incor-
porated counts were determined.
Because blood cells of individual donors differ considerably in the
absolute values of NK activity as well as in cytokine production,
regardless of whether they are obtained from normal controls or
patients, mean values of pretreatment v postreatment values could
not be compared. Therefore, statistical analyses of the data pairs
from individual patients obtained before and after TNF treatment
were performed using the Wilcoxon signed-rank test. P values were
calculated for assessment of significance.
RESULTS
Determination ofNK cell activity. NK cell activity was
determined by a whole blood technique in samples from
cancer patients before and immediately after 24-hour infu-
sion of rhTNF. A decrease in NK cell activity was observed
in most patients after treatment. This was confirmed in a
second series of experiments in which PMNLs were sepa-
rated from peripheral blood and tested in the NK cell assay
(Fig 1). Again, in this experiment using PMNLs, the NK
cell activity was significantly decreased after rhTNF treat-
ment of the patients.
Determination of Leul 1-positive cells. To determine
whether the percentage of cells bearing the surface marker
U, 25
>‘
 20
15
25
20
.,-, 15
 10
5
before after before after
rtonstimtjoted TNF treatment stinijated
700
Table 1 . Percentage of Leul 1 -Positive Cells in PMNLs of Patients
Before and After rhTNF Treatment
The percentages of Leu 1 1  cells in the PMNL preparations obtained
from patients before and after rhTNF treatment were determined by
direct immunofluorescenCe using FITC-Iabeled Leu 1 1 a antibodies.
after
nonstimWted TNF freaUeM stirsiated
Fig 3. IL-i production of PMNL preparation as described in
legend to Fig 2. Reduction of spontaneous IL-i production after
treatment was statistically significant (P - .046). For the stimu-
lated cultures. reduction was highly significant (P .004).
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CD16 (Leull) that is preferentially responsible for NK
activity2’ was changed after treatment, the PMNLs of five
patients were stained with FITC-labeled antibodies to Leu-
1 la, and positive cells were counted (Table 1). rhTFN
treatment resulted in a marked decrease in the percentage of
CDI6-positive cells as compared with the respective pre-
treatment values. Absolute numbers of CD16-positive cells
were also decreased posttreatment (data not shown).
Determination of TNFproduction. The capacity to pro-
duce monokines was used as a measure of monocyte func-
tions in PMNL preparations from cancer patients (Fig 2).
Low spontaneous TNF production occurred only in three of
nine PMNL preparations, but all nine cultures were induc-
ible for TNF production with Staph aureus. TNF production
of PMNLs from patients who had received rhTNF infusion
was significantly reduced in the three cases with low sponta-
neous release, as well as in all stimulated cultures. The values
obtained with the ELISA test were confirmed by a conven-
tional biologic TNF assay [cytotoxicity on L929 fibrosar-
coma cells in the presence of actinomycin D’6 (data not
shown)]. The existence of inhibitory substances in the post-
treatment samples was excluded by experiments in which
these samples were added to defined concentrations of TNF
(data not shown).
Determination ofJL-1 production. The pattern of IL-i
activity followed closely the TNF activity when the same
PMNL supernatants were tested in the IL-i costimulator
assay (Fig 3). Before rhTNF treatment, low spontaneous
IL-I activity was measured in the supernatants ofalmost all
unstimulated cell cultures. High IL-I titers were detected,
however, in all nine cultures when stimulated with Staph
aureus. Again after treatment with rhTNF, PMNLs signifi-
cantly lost their capacity to produce IL-I . This phenomenon
was even more pronounced in supernatants from Staph
aureus-stimulated PMNL cultures of the same patients.
Determination of lymphoproliferative responses. PHA-
stimulated and Con A-stimulated lymphoproliferation was
significantly reduced after rhTNF treatment when corn-
pared with the values of PMNLs from the same patients
before rhTNF infusion (Table 2). The proliferation stimu-
lated by Con A was more affected by TNF treatment than
that stimulated by PHA. The more pronounced reduction in
lymphoproliferation after TNF treatment in Con A-stimu-
rhTNF Treatment
Before After
Patient (% Leul 1  Cells)
1 8.27 0.33
2 15.67 2.67
3 13.62 1.02
4 19.32 3.19
5 10.12 1.12
Fig 2. TNF production of PMNL preparations obtained from
nine patients before and after rhTNF treatment. Reduction of
spontaneous TNF production after treatment was statistically
significant (P .054). For the stimulated cultures. reduction was
highly significant (P - .004).
lated (93%) v PHA-stimulated cultures (57%) was signifi-
cant.
Differential counts of blood cells from the patients did not
differ significantly from normal controls. After TNF treat-
ment, some patients had a mild leukopenia (data not
shown).
DISCUSSION
NK activity and monokine production capacity were
markedly impaired in the PMNLs from individual patients
who had received rhTNF infusion as compared with the
same patients’ pretreatment patients’ values. This finding
was surprising in light of recent reports that TNF enhanced
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Table 2. Lymphoproliferative Responses of Blood Cells From
Patients Before and After rhTNF Treatment
Stimulation
PHA
Patient Before After
Before
(cpm x
After
1O)
ConA
Before After
1 7.5 0.5 4.9 1.8 21.2 6.8
2 0.5 0.8 144.3 49.6 116.0 1.5
3 0.9 1.1 15.4 12.0 6.2 2.1
4 2.0 2.1 41.7 20.6 56.9 2.1
5 1.4 0.4 47.9 3.1 42.2 0.2
6 1.5 0.6 10.5 58.2 46.0 0.4
7 1.8 0.6 46.2 18.2 17.5 0.7
‘Whole blood samples obtained from patients before and after rhTNF
treatment were cultured either without stimulus or with PHA or ConA.
3H-TdR incorporation was determined as a measure for lymphoprolifera-
tion. Reduction of lymphoproliferation after treatment was statistically
significant (for the unstimulated cultures P = .088 and for PHA-
stimulated and ConA-stimulated cultures P = .009).
NK activity,22 and activated monocytes in vitro.9 Our own
in vitro data showed that even enhanced TNF production
could be expected,8 and our unpublished in vitro results with
human monocytes. However, both NK activity and mono-
kine production were significantly reduced after in vivo
rhTNF application. On the assumption that CD16 on large
granular lymphocytes (LGLs) represents a specific marker
for NK cells,2’ the disappearance of Leul 1 positive cells
might explain the loss of NK activity on a cellular level.
Functional inactivation would be one of the possible mecha-
nisms. However, how rhTNF treatment caused the disap-
pearance of these cells from the circulation is still open to
speculation. Reduction of NK activity can also be partly
associated with the reduction of TNF production capacity
after rhTNF treatment. Recent reports describe partial
inhibition of NK activity by antibodies to TNF, implying
that part of the NK activity could indeed be caused by
TNF.23’24 However, TNF has never been implicated in the
NK-mediated cytotoxicity measured on K562 target cells.
Monocytes and macrophages are the classical producers
for TNF and IL-i. However other cell types, like LGLs can
also produce these mediators.24’25 Thus, the disappearance of
the CDI6-positive cells could partly explain the drop in
monokine production as well. Furthermore, it is possible that
in addition to the reduced number of CDI6 positive cells,
monocytes may also have been depleted from the circulation,
even though no significant leukopenia or monocytopenia was
detectable in routinely performed blood counts. This hypoth-
esis is supported by in vivo experiments in a mouse model in
which drastic monocytopenia was found after TNF applica-
tion.26 TNF has been described to reorganize human vascular
endothelial cell monolayers and to increase adherence of
endothelial cells for leukocytes.27 This could be the molecular
mechanism for the drastic reduction of these cells in circulat-
ing blood. Another explanation may be a direct toxic effect of
rhTNF for the cells responsible for NK and TNF activity. To
our knowledge, however, no indication for such toxic action
of TNF for the cells relevant for NK activity or monokine
production has been described in the literature.
The findings that preferentially Con A-induced and, to a
much less extent PHA-induced, lymphoproliferation were
reduced after rhTNF treatment also indicated that T cells
are not directly affected, but rather that monocyte functions
appear to be impaired by the rhTNF treatment. This conclu-
sion is based on the established finding that PHA-induced
lymphocyte activation is much less dependent on monocytes
than is Con A-induced proliferation.
More detailed studies are in progress concerning the fate
of LGLs and monocytes and their functional status in
rhTNF-treated patients. In addition, studies on patients who
have received several infusions of rhTNF during their treat-
ment will be performed to assemble a comprehensive picture
of the effects of rhTNF application during therapy. The
decrease in immune function we described was an early
transient effect, since the same parameters in six patients
were back to pretreatment levels when tested again before
the next cycle of TNF application. Thus, the period of
depression in function of NK cells and monocytes appears to
be a transient phenomenon followed by complete recovery.
These findings might provide insight into the complex mech-
anism of in vivo action of rhTNF. The determination of the
clinical implications of the described findings must await
completion of the ongoing trials and long-term studies.
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